Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.
Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?
Overview
Pfizer (NYSE: PFE) has a shockingly high dividend yield of 6.8%. The S&P 500 Index (SNPINDEX: ^GSPC) has a 1% yield, and the average pharmaceutical stock's yield is roughly 1.5%. Given that huge disparity, it looks like Pfizer's yield is too good to be true.
There are reasons for the high yield that need to be monitored. However, management doesn't seem too worried about the dividend. Here are some reasons why, and why you might want to buy ultra-high-yield Pfizer.
Details
Pfizer's dividend, like all dividends, is paid at the discretion of the board of directors. That said, the company's management team has been very clear about its support for the dividend. The dividend was mentioned directly on two slides in the first-quarter 2026 earnings presentation. One slide, focused on 2026 capital allocation priorities, stated that the company wants to "maintain and grow our dividend." A second slide, directed at longer-term growth, made "maintain dividend" a stated goal.
Source
Originally published at www.fool.com.
Related Articles
- Blackstone, Brookfield and KKR sign $16 billion deal with Kuwait for oil pipeline network
- This ETF Has More Than Doubled the S&P 500's Returns This Year, but Be Aware of This One Issue It Could Face in the Second Half of the Year.
- Does crypto make your portfolio less risky? Only if you do it right, experts say